1Blasko J C,Grimm P d,Ashley R,etal.Palladium-103 brachytherapy for prostate carcinoma.IntJ Radiat Oncol Biol Phys,2000,46:839-850.
2Wu A,Zwicker D,Sternick E S.Tumor dose specification of I-125 seed implants.MedPhys,1985,12:27.
3Taplin M E,Bubley G J,Ko Y J,etal.Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.Cancer Res,1999,59:2511-2515.
4Myers R B,Kudlow J E,Grizzle W E.Expression of transforming growth factor-alpha,epidermal growth factor and the epidermal growth factor recepor in adenocarcinoma of the prostate and benign prostatic hyperplasia.Mod Pathol,1993,6:733-737.
5Scott W W,Boyd H Z.Combined hormone control therapy and radical prostatectomy in the treatment of selected cases of the prostate:a retrospective study based upon 25 years of experience.J Urol,1969,101:86-92.
6Kish J A.Neoadjuvant androgen ablation in localized carcinoma of the prostate.Cancer-controrl,2001,8:155-162.
7Stone N N,Stock R G,Unger P.Effects of Neoadjuvant normonal therapy on prostate biopsy results after 125I and 103Pd seed implantation.Mol Urol,2000,4:163-168.
8Raben A, Muchacxak B. Brachytherapy for non-small cell lung cancer and selected neoplasms of the chest[J]. Chest, 1997,112:276s～286s.
2Weikert S, Ljungberg B. Contemporary epidemiology of renal cell carcinoma:perspectives of primary p, revention[J]. World J Urol, 2010, 28:247.
3Joslyn SA,Sirintrapun SJ, Konety BR.Impact of lyrnphadenectomy and nodalburden in renal cell carcinoma:retrospective analysis of the national surveiUance,epidemiology, and end results database[J].Urol, 2005, 65(4):675.
4Blom JH,van Poppel H, Marechal JM, et al. Radical nephrectomy with and without lymphnode dissection: final results of European organization for research and treatment of cancer (EORTC) randomized phase III protocol 30881.[J]. Eur Urol, 2009, 55:28.
5Sagalowsky AI, Kadesky KT, Ewalt DW, et al. Factors influencing adrenal metastasis in renal cell carcinoma[J].J Urol, 1994, 151(5):1181.
6Kuczyk M,Wegener G, Jonas U. The therapeutic value of adrenalectomy in case of solitary metastatic spread originating from primary renal cell cancer[J].Eur Urol, 2005, 48(2):252.
7Luciani LG, Cestari R, Tallarigo C. Incidental renal cell carcinoma-age and stage characterization and clinical implications: study of 1092 patients (1982-1997) [J]. Urology, 2000, 56 ( 1 ) : 58.
8Becker F, Siemer S, Humke U, et al. Elective nephron sparing surgery should become standard treatment for smallunilateral renal cell carcinoma:Long-term survivaldata of 216 patients[J]. Eur Uro, 2006, 49 (2): 308.
9Lau WK, Blute ML, Weaver AL, et al. Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney[J]. Mayo Clin Proc, 2000, 75 (12) : 1236.
10Flanigan RC, Mlckisch G, Sylvester R, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer:a combined analysis[J]. J Urol, 2004, 171(3):1071.
